LENNAR CORP /NEW/ (LEN) Stock News

Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance.

Block & Leviton is investigating Lennar Corporation for potentially misleading investors about home delivery numbers in fiscal Q3 2026. The investigation focuses on whether Lennar artificially inflated delivery figures through purchases by its spinoff company Millrose Properties in the final week of the quarter. Lennar's stock fell on October 5, 2026, following an analyst downgrade of Millrose.

Lennar reported $8.05 billion in revenue for Q3 2026, down 8.7% year-over-year and missing consensus estimates by 3.44%. EPS of $1.23 fell short of the $1.29 estimate. Key operational metrics also disappointed, including lower home deliveries (20,840 vs. 21,439 estimated), fewer new orders (20,879 vs. 21,300), and reduced active communities. The stock carries a Zacks Rank #5 (Strong Sell) rating.

Lennar stock fell 3.84% in the latest trading session, underperforming the broader market. The homebuilder faces headwinds with projected EPS declining 34.5% and revenue down 5.42% for the upcoming quarter. The company carries a Zacks Rank of #4 (Sell) and trades at a premium valuation compared to its industry peers.

Lennar (LEN) closed down 2.57% in the latest trading session. The homebuilder faces significant headwinds with projected EPS declining 34.50% and revenue falling 5.42% for the upcoming quarter. Full-year estimates show earnings down 32.26% and revenue down 5.6% year-over-year. The stock carries a Zacks Rank of #4 (Sell) with a Forward P/E of 15.82, trading at a premium to its industry average.

A class action lawsuit has been filed against Helen of Troy Limited for allegedly misleading investors about Project Pegasus, a restructuring initiative. The company claimed the project was delivering efficiencies and cost savings, but in reality lacked sufficient resources and budget. When the truth emerged in July 2024, the company reported a 49% EPS decline and cut full-year revenue guidance by over 20%, causing the stock to plummet 27.7%. Investors who purchased shares between April 24, 2024, and October 8, 2025, have until August 3, 2026, to apply as lead plaintiff.

Avcon Industries, a subsidiary of Butler National Corporation, has received two FAA Supplemental Type Certificates (STCs) for the Bombardier Challenger 604, 605, and 650 aircraft platforms. The certifications approve installation of fuselage underside rail mounting provisions and radome systems for sensors and mission equipment, expanding Avcon's special mission aircraft modification portfolio and positioning the Challenger platforms as attractive options for customers requiring greater range, endurance, and payload capacity.

A class action lawsuit has been filed against Helen of Troy Limited for allegedly misleading investors about Project Pegasus, a restructuring initiative. The company claimed the project was delivering efficiencies and cost savings, but in reality lacked sufficient resources and budget. When the truth emerged in July 2024, the company reported a 49% EPS decline and cut full-year revenue guidance by over 20%, causing stock to drop 27.7%. Investors who purchased shares between April 24, 2024, and October 8, 2025, can join the lawsuit.

LENZ Therapeutics announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100) in Greater China through an Asset Purchase Agreement with Corxel Pharmaceuticals. The New Drug Application for LNZ100 was submitted to China's NMPA in September 2025 with approval anticipated in Q1 2027. LENZ is eligible to receive up to $85 million in regulatory and sales milestones plus tiered royalties on net sales.

Mission Bank has expanded its Bakersfield-based Agricultural Lending Team by hiring three industry veterans: Relationship Managers John Etchison and Eric Schoenheide, and Relationship Associate Eliza Hernandez. The team brings nearly 75 years of combined experience in ag lending and will operate from the Downtown Bakersfield Business Banking Center under Ag Division Manager Rob Hallum. This marks the second new team added by Mission Bank in 2026.

Five Iron Golf opened its first Texas location in Fort Worth's Near Southside district, celebrating with tournament-week specials tied to the Charles Schwab Challenge at Colonial Country Club. The 10,000-square-foot venue features 12 Trackman simulators, a full-service bar, and entertainment amenities. Special offers include complimentary simulator time for anyone named Charles and appetizers for tournament attendees.